Abstract
Background
PKU is the most common hereditary metabolic disease. Considering the severe complications caused by the lack of timely diagnosis of this disease, it is important to carry out the newborn screening process properly.
Aim
This study aims to determine the incidence of phenylketonuria (PKU) based on the results of the neonatal screening program and evaluate the indicators of this program in Sirjan City from 2012 to 2019.
Methods
The present study was across-section descriptive, and all screening babies were examined from 2012 to 2019. Screening information was obtained from data recorded in the neonatal screening program and patient information from the national form of epidemiological investigation of genetic diseases in the Kerman Health Department. Excel software was used to draw charts. Descriptive statistics were used to describe the variables. Information was provided as a frequency table and chart.
Results
The overall screening coverage was 95.3%. Among this, 93.2% of infants were screened during the 3 to 5 days of life. The incidence of PKU was found to be 1.33 in 10,000 live births. Around 0.44% of the samples were inappropriate, and the percentage of inappropriate samples was from the beginning of the program and monitored across each year. On the first visit to the PKU treatment center, 50% of infants were below 2 weeks. About 100% of patients identified in screening were the first child in the family, and around 83.3% of parents were consanguineous.
Conclusion
The incidence of PKU in Sirjan is in line with the national average. Implementation of the screening program showed a significant impact on the timely diagnosis and the onset of patients. It is necessary to increase household awareness about the consequences of consanguineous marriages, especially in areas with a high prevalence of PKU.
Publisher
Bentham Science Publishers Ltd.
Reference37 articles.
1. Sumaily KM, Mujamammi AH.
Phenylketonuria: A new look at an old topic, advances in laboratory diagnosis, and therapeutic strategies.
Int J Health Sci
2017;
11
(5)
: 63-70.
2. Sailer M, Elizondo G, Martin J, Harding CO, Gillingham MB.
Nutrient intake, body composition, and blood phenylalanine control in children with phenylketonuria compared to healthy controls.
Mol Genet Metab Rep
2020;
23
: 100599.
3. Harding CO.
Progress toward cell‐directed therapy for phenylketonuria.
Clin Genet
2008;
74
(2)
: 97-104.
4. Trefz FK.
Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: A phase III, randomized, double-blind, placebo-controlled study.
J Pediat
2009;
154
(5)
: 700-.
5. Mo X, Li Y, Tang A, Ren Y.
Simultaneous determination of phenylalanine and tyrosine in peripheral capillary blood by HPLC with ultraviolet detection.
Clin Biochem
2013;
46
(12)
: 1074-8.